Print Page
|
E-mail Page
|
RSS Feeds
|
E-mail Alerts
|
Financial Tear Sheet
SEC Filings
Form 10-K
SYNTA PHARMACEUTICALS CORP filed this
Form 10-K
on 03/11/10
Document Outline
Entire Document (2005.3 KB)
Subdocument 1 - 10-K - FORM 10-K
Page 1 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Page 2 - PART I
Page 3 - CRACM Ion Channel Program
Page 4 - Our Drug Candidate Pipeline
Page 5 - Oncology Programs
Page 6 - in vitro
Page 7 - N/A
Page 8 - Elesclomol (Oxidative Stress Inducer)
Page 9 - STA-9584's Mechanism of Action
Page 10 - Apilimod Mechanism of Action
Page 11 - in vitro
Page 12 - in silico
Page 13 - STA-9090 Manufacturing
Page 14 - Patents and Proprietary Rights
Page 15 - Government Regulation and Product Approval
Page 16 - Phase 1.
Page 17 - N/A
Page 18 - Expedited Review and Approval
Page 19 - Orphan Drug Designation
Page 20 - N/A
Page 21 - N/A
Page 22 - Employees
Page 23 - Risks Related to Our Financial Position and Need for Additional Capital
Page 24 - If we fail to obtain the funding necessary to support our operations, we will be unable to successf
Page 25 - Raising additional capital may cause dilution to existing stockholders, restrict our operations or
Page 26 - If we do not obtain the required regulatory approvals, we will be unable to market and sell our dru
Page 27 - N/A
Page 28 - If clinical trials for our drug candidates are prolonged, delayed or suspended, we may be unable to
Page 29 - Failure to comply with foreign regulatory requirements governing human clinical trials and marketin
Page 30 - If side effects or toxicities increase or are identified during the time our drug candidates are in
Page 31 - While we choose to test our drug candidates in specific clinical indications based in part on our u
Page 32 - We rely on third parties to conduct our clinical trials and nonclinical safety assessment studies,
Page 33 - N/A
Page 34 - If we do not establish additional collaborations, we may have to alter our development plans.
Page 35 - N/A
Page 36 - N/A
Page 37 - Litigation or other proceedings or third-party claims of intellectual property infringement would r
Page 38 - We may be subject to claims that we have wrongfully hired an employee from a competitor or that we
Page 39 - N/A
Page 40 - N/A
Page 41 - STA-9090.
Page 42 - We are subject to federal and state laws prohibiting "kickbacks" and false or fraudulent claims, an
Page 43 - If we make strategic acquisitions, we will incur a variety of costs and might never realize the ant
Page 44 - N/A
Page 45 - Provisions of our charter, bylaws, and Delaware law may make an acquisition of us or a change in ou
Page 46 - Item 2. PROPERTIES
Page 47 - PART II
Page 48 - Stock Performance Graph
Page 49 - Item 6. SELECTED FINANCIAL DATA
Page 50 - As of December 31,
Page 51 - N/A
Page 52 - STA-9090 Preclinical Results
Page 53 - STA-9090 Ongoing Clinical Trials
Page 54 - N/A
Page 55 - STA-9584 (Vascular Disrupting Agent)
Page 56 - Roche CRACM Inhibitor Alliance
Page 57 - Research and Development
Page 58 - General and Administrative
Page 59 - Marketable Securities
Page 60 - Collaborative Development, Commercialization and License Agreement with GSK
Page 61 - Collaborative License Agreement with Roche
Page 62 - Stock-Based Compensation
Page 63 - Consolidated Results of Operations
Page 64 - 2008 as compared to 2007
Page 65 - N/A
Page 66 - General and Administrative Expense
Page 67 - Other (Expense) Income, net
Page 68 - Cash Flows
Page 69 - Contractual Obligations and Commitments
Page 70 - N/A
Page 71 - N/A
Page 72 - Tax Loss Carryforwards
Page 73 - Capital Market Risk.
Page 74 - Report of Independent Registered Public Accounting Firm
Page 75 - N/A
Page 76 - PART III
Page 77 - PART IV
Page 78 - Exhibit Number
Page 79 - N/A
Page 80 - N/A
Page 81 - N/A
Page 82 - N/A
Page 83 - SIGNATURES
Page 84 - INDEX TO CONSOLIDATED FINANCIAL STATEMENTS SYNTA PHARMACEUTICALS CORP. Years ended December 31, 200
Page 85 - Report of Independent Registered Public Accounting Firm
Page 86 - N/A
Page 87 - SYNTA PHARMACEUTICALS CORP. Consolidated Balance Sheets (in thousands, except share and per share a
Page 88 - SYNTA PHARMACEUTICALS CORP. Consolidated Statements of Operations (in thousands, except share and p
Page 89 - SYNTA PHARMACEUTICALS CORP. Consolidated Statements of Stockholders' Equity (Deficit) and Comprehen
Page 90 - SYNTA PHARMACEUTICALS CORP. Consolidated Statements of Cash Flows (in thousands)
Page 91 - SYNTA PHARMACEUTICALS CORP. Notes to Consolidated Financial Statements
Page 92 - SYNTA PHARMACEUTICALS CORP.
Page 93 - N/A
Page 94 - N/A
Page 95 - N/A
Page 96 - N/A
Page 97 - N/A
Page 98 - N/A
Page 99 - N/A
Page 100 - N/A
Page 101 - N/A
Page 102 - N/A
Page 103 - N/A
Page 104 - N/A
Page 105 - N/A
Page 106 - N/A
Page 107 - N/A
Page 108 - N/A
Page 109 - N/A
Page 110 - N/A
Page 111 - N/A
Page 112 - N/A
Page 113 - N/A
Page 114 - N/A
Page 115 - N/A
Subdocument 2 - EX-10.29 - EXHIBIT 10.29
Page 1 - Exhibit 10.29
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Subdocument 3 - EX-10.30 - EXHIBIT 10.30
Page 1 - Exhibit 10.30
Page 2 - N/A
Page 3 - 2.
Page 4 - provided that
Page 5 - 6.
Page 6 - With a copy to:
Page 7 - 14.
Page 8 - N/A
Subdocument 4 - EX-10.31 - EXHIBIT 10.31
Page 1 - Exhibit 10.31
Page 2 - N/A
Page 3 - 2.
Page 4 - provided that
Page 5 - 6.
Page 6 - With a copy to:
Page 7 - 14.
Page 8 - N/A
Subdocument 5 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Page 2 - N/A
Subdocument 6 - EX-23.2 - EXHIBIT 23.2
Page 1 - Exhibit 23.2
Page 2 - N/A
Subdocument 7 - EX-31.1 - EXHIBIT 31.1
Page 1 - Exhibit 31.1
Page 2 - N/A
Subdocument 8 - EX-31.2 - EXHIBIT 31.2
Page 1 - Exhibit 31.2
Page 2 - N/A
Subdocument 9 - EX-32.1 - EXHIBIT 32.1
Page 1 - Exhibit 32.1
Page 2 - N/A
ABOUT
|
PIPELINE
|
CLINICAL TRIALS
|
TECHNOLOGY
|
INVESTORS
|
CAREERS
Copyright ©
2009
Synta Pharmaceuticals Corp. All rights reserved.
Terms of Use
